Poliovirus Tumor Vaccine for Breast Cancer Micro-Metastases.
Annual rept. 15 Aug 94-14 Aug 95,
ALABAMA UNIV IN BIRMINGHAM
Pagination or Media Count:
The underlying reason for failure to cure patients diagnosed with breast cancer is the presence of micrometastases in approximately one third of the breast cancer patients. The stimulation of anti-tumor immune responses represents one of the most effective ways to treat low tumor burdens that are microscopically or clinically occult. The objective of our proposal is to determine whether a poliovirus replicon vaccine strategy engineered to express human CEA and, in the future, the HER2neu oncogene, can induce systemic immunity and eradication of micrometastases. During the first year of our project, we have constructed poliovirus replicons which express CEA. Mice given these replicons generate anti-CEA antibodies. We have constructed replicons which contain the extracellular domain of the HER2neu oncogene and will be testing the immunogenicity in mice. The significance of these studies is that we have now characterized the appropriate replicons that will be used to establish route of administration for generating an immune response against CEA or HER2neu prior to tumor challenge. The results of these studies will provide essential preclinical observations that will be relevant to the starting of human breast cancer trials targeted against cells that express CISA or HER2neu.
- Anatomy and Physiology